Brain imaging in Alzheimer disease
KA Johnson, NC Fox… - Cold Spring …, 2012 - perspectivesinmedicine.cshlp.org
Imaging has played a variety of roles in the study of Alzheimer disease (AD) over the past
four decades. Initially, computed tomography (CT) and then magnetic resonance imaging …
four decades. Initially, computed tomography (CT) and then magnetic resonance imaging …
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
Alzheimer's disease (AD) is a progressive age-related neurodegenerative disease. At the
time of clinical manifestation of dementia, significant irreversible brain damage is already …
time of clinical manifestation of dementia, significant irreversible brain damage is already …
Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease
JB Pereira, S Janelidze, R Ossenkoppele… - Brain, 2021 - academic.oup.com
It is currently unclear how amyloid-β and tau deposition are linked to changes in synaptic
function and axonal structure over the course of Alzheimer's disease. Here, we assessed …
function and axonal structure over the course of Alzheimer's disease. Here, we assessed …
Assessing synaptic density in Alzheimer disease with synaptic vesicle glycoprotein 2A positron emission tomographic imaging
Importance Synaptic loss is well established as the major structural correlate of cognitive
impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could …
impairment in Alzheimer disease (AD). The ability to measure synaptic density in vivo could …
[HTML][HTML] In Alzheimer's disease, 6-month treatment with GLP-1 analog prevents decline of brain glucose metabolism: randomized, placebo-controlled, double-blind …
In animal models, the incretin hormone GLP-1 affects Alzheimer's disease (AD). We
hypothesized that treatment with GLP-1 or an analogue of GLP-1 would prevent …
hypothesized that treatment with GLP-1 or an analogue of GLP-1 would prevent …
Amyloid deposition, hypometabolism, and longitudinal cognitive decline
SM Landau, MA Mintun, AD Joshi… - Annals of …, 2012 - Wiley Online Library
Objective: Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI)
population, we examined (1) cross‐sectional relationships between amyloid deposition …
population, we examined (1) cross‐sectional relationships between amyloid deposition …
Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer's disease: A tracer kinetic modeling study
[11C] UCB-J PET for synaptic vesicle glycoprotein 2 A (SV2A) has been proposed as a
suitable marker for synaptic density in Alzheimer's disease (AD). We compared [11C] UCB-J …
suitable marker for synaptic density in Alzheimer's disease (AD). We compared [11C] UCB-J …
Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB–PET longitudinal study
Amyloid-β deposition in Alzheimer's disease is thought to start while individuals are still
cognitively unimpaired and it is hypothesized that after an early phase of fast accumulation …
cognitively unimpaired and it is hypothesized that after an early phase of fast accumulation …
Sensors for positron emission tomography applications
Positron emission tomography (PET) imaging is an essential tool in clinical applications for
the diagnosis of diseases due to its ability to acquire functional images to help differentiate …
the diagnosis of diseases due to its ability to acquire functional images to help differentiate …
18F‐FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
M Vacante, C Hyde, S Martin… - Cochrane Database …, 2015 - cochranelibrary.com
Background ¹⁸F‐FDFG uptake by brain tissue as measured by positron emission
tomography (PET) is a well‐established method for assessment of brain function in people …
tomography (PET) is a well‐established method for assessment of brain function in people …